Patrick J. Heron - 23 Jun 2025 Form 4 Insider Report for HilleVax, Inc. (HLVX)

Role: Director
Signature: /s/ Paul Bavier, Attorney-in-Fact for Patrick Heron
Issuer symbol: HLVX
Transactions as of: 23 Jun 2025
Net transactions value: $0
Form type: 4
Filing time: 25 Jun 2025, 17:07:01 UTC
Previous filing: 17 Jun 2025
Next filing: 30 Sep 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Heron Patrick J	Director	C/O HILLEVAX, INC.,, 321 HARRISON AVE, SUITE 500, BOSTON	/s/ Paul Bavier, Attorney-in-Fact for Patrick Heron	25 Jun 2025	0001365617

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	HLVX	Common Stock	Award	$0	+17,199		$0.000000	17,199	23 Jun 2025	Direct	F1
holding	HLVX	Common Stock						8,535,337	23 Jun 2025	By Frazier Life Sciences X, L.P.	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The Restricted Stock Units ("RSUs") were granted on June 23, 2025 pursuant to the Registrant's Non-Employee Director Compensation Program. 100% of the total number of RSUs granted shall vest on the first to occur of (i) the first anniversary of the date of grant or (ii) a Change in Control (as defined in the Registrant's 2022 Incentive Award Plan), in each case, subject to the non-employee director continuing in service on the Registrant's board of directors through such vesting date.
F2	The shares reported herein are held of record by Frazier Life Sciences X, L.P. ("FLS X"). The general partner of FLS X is FHMLS X, L.P., and the general partner of FHMLS X, L.P. is FHMLS X, L.L.C. James Topper, M.D., Ph.D., and Patrick Heron are the sole managing members of FHMLS X, L.L.C. and share voting and investment power of the securities held by FLS X. Dr. Topper and Mr. Heron disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein.

Content

The Restricted Stock Units ("RSUs") were granted on June 23, 2025 pursuant to the Registrant's Non-Employee Director Compensation Program. 100% of the total number of RSUs granted shall vest on the first to occur of (i) the first anniversary of the date of grant or (ii) a Change in Control (as defined in the Registrant's 2022 Incentive Award Plan), in each case, subject to the non-employee director continuing in service on the Registrant's board of directors through such vesting date.

The shares reported herein are held of record by Frazier Life Sciences X, L.P. ("FLS X"). The general partner of FLS X is FHMLS X, L.P., and the general partner of FHMLS X, L.P. is FHMLS X, L.L.C. James Topper, M.D., Ph.D., and Patrick Heron are the sole managing members of FHMLS X, L.L.C. and share voting and investment power of the securities held by FLS X. Dr. Topper and Mr. Heron disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein.